Ok Biotech Co Ltd
OK Biotech Co., Ltd. develops, manufactures, markets, and sells blood glucose monitoring systems and homecare healthcare devices in Taiwan and internationally. It also offers OTC hearing aids, multi-frequency therapy devices, and factory setup solutions. The company was founded in 2004 and is based in Hsinchu City, Taiwan.
Ok Biotech Co Ltd (4155) - Total Liabilities
Latest total liabilities as of September 2025: NT$1.37 Billion TWD
Based on the latest financial reports, Ok Biotech Co Ltd (4155) has total liabilities worth NT$1.37 Billion TWD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Ok Biotech Co Ltd - Total Liabilities Trend (2009–2024)
This chart illustrates how Ok Biotech Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Ok Biotech Co Ltd Competitors by Total Liabilities
The table below lists competitors of Ok Biotech Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Blackboxstocks Inc
NASDAQ:BLBX
|
USA | $4.03 Million |
|
Doxa AB
ST:DOXA
|
Sweden | Skr2.07 Billion |
|
Kunyue Development Co Ltd
TWO:5206
|
Taiwan | NT$12.72 Billion |
|
Twinhead International Corp
TW:2364
|
Taiwan | NT$916.61 Million |
|
Precision System Science Co. Ltd.
PINK:PCNEF
|
USA | $1.18 Billion |
|
Southeastern Banking Corp
PINK:SEBC
|
USA | $522.34 Million |
Liability Composition Analysis (2009–2024)
This chart breaks down Ok Biotech Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.56 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.35 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Ok Biotech Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Ok Biotech Co Ltd (2009–2024)
The table below shows the annual total liabilities of Ok Biotech Co Ltd from 2009 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$1.13 Billion | +67.85% |
| 2023-12-31 | NT$672.26 Million | -44.66% |
| 2022-12-31 | NT$1.21 Billion | +9.47% |
| 2021-12-31 | NT$1.11 Billion | +39.43% |
| 2020-12-31 | NT$795.91 Million | -13.34% |
| 2019-12-31 | NT$918.40 Million | +57.60% |
| 2018-12-31 | NT$582.73 Million | -14.06% |
| 2017-12-31 | NT$678.07 Million | +23.14% |
| 2016-12-31 | NT$550.64 Million | +11.16% |
| 2015-12-31 | NT$495.36 Million | -11.72% |
| 2014-12-31 | NT$561.11 Million | -33.75% |
| 2013-12-31 | NT$847.00 Million | +160.10% |
| 2012-12-31 | NT$325.65 Million | +77.65% |
| 2011-12-31 | NT$183.31 Million | +93.76% |
| 2010-12-31 | NT$94.60 Million | +13.41% |
| 2009-12-31 | NT$83.42 Million | -- |